Association of HLA Polymorphisms with Post-transplant Lymphoproliferative Disorder in Solid-Organ Transplant Recipients

被引:40
作者
Reshef, R. [1 ]
Luskin, M. R. [1 ]
Kamoun, M. [2 ]
Vardhanabhuti, S. [3 ]
Tomaszewski, J. E. [2 ]
Stadtmauer, E. A. [1 ]
Porter, D. L. [1 ]
Heitjan, D. F. [3 ]
Tsai, De E. [1 ]
机构
[1] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA
基金
美国国家卫生研究院;
关键词
HLA; PTLD; solid-organ transplantation; EPSTEIN-BARR-VIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLASS-II ALLELES; ANTIGEN CLASS-II; HODGKIN-LYMPHOMA; KAPOSIS-SARCOMA; DONOR ORIGIN; INFECTIOUS-MONONUCLEOSIS; NASOPHARYNGEAL CARCINOMA; LIVER-TRANSPLANTATION;
D O I
10.1111/j.1600-6143.2011.03454.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
The association between HLA polymorphisms and PTLD was investigated in a case-control study, comparing 110 predominantly adult solid-organ transplant recipients who developed PTLD to 5601 who did not. Donor and recipient HLA were analyzed. We detected a significant association between recipient HLA-A26 and the development of PTLD (OR 2.74; p = 0.0007). In Caucasian recipients, both recipient and donor HLA-A26 were independently associated with development of PTLD (recipient A26 OR 2.99; p = 0.0004, donor A26 OR 2.81; p = 0.002). Analysis of HLA-A and -B haplotypes revealed that recipient HLA-A26, B38 haplotype was strongly correlated with a higher incidence of EBV-positive PTLD (OR 3.99; p = 0.001). The common ancestral haplotype HLA-A1, B8, DR3, when carried by the donor, was protective against PTLD (OR 0.41; p = 0.05). Several other HLA specificities demonstrated associations with clinical and pathological characteristics as well as survival. These findings demonstrate the importance of HLA polymorphisms in modulating the risk for PTLD, and may be useful in risk stratification and development of monitoring and prophylaxis strategies.
引用
收藏
页码:817 / 825
页数:9
相关论文
共 59 条
[1]   Preemptive Management of Epstein-Barr Virus Reactivation After Hematopoietic Stem-Cell Transplantation [J].
Ahmad, Imran ;
Cau, Nguyen V. ;
Kwan, John ;
Maaroufi, Younes ;
Meuleman, Nathalie ;
Aoun, Mickael ;
Lewalle, Philippe ;
Martiat, Philippe ;
Crokaert, Francoise ;
Bron, Dominique .
TRANSPLANTATION, 2009, 87 (08) :1240-1245
[2]  
ARMES JE, 1994, CANCER, V74, P2436, DOI 10.1002/1097-0142(19941101)74:9<2436::AID-CNCR2820740908>3.0.CO
[3]  
2-S
[4]   HLA antigens and post renal transplant lymphoproliferative disease: HLA-B matching is critical [J].
Bakker, NA ;
van Imhoff, GW ;
Verschuuren, EAM ;
van Son, WJ ;
van der Heide, JJH ;
Lems, SPM ;
Veeger, NJGM ;
Kluin, PM ;
Kluin-Nelemans, HC ;
Hepkema, BG .
TRANSPLANTATION, 2005, 80 (05) :595-599
[5]   Monitoring and Preemptive Rituximab Therapy for Epstein-Barr Virus Reactivation after Antithymocyte Globulin Containing Nonmyeloablative Conditioning for Umbilical Cord Blood Transplantation [J].
Blaes, Anne H. ;
Cao, Qing ;
Wagner, John E. ;
Young, Jo-Anne H. ;
Weisdorf, Daniel J. ;
Brunstein, Claudio G. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (02) :287-291
[6]   A mechanism for the HLA-A*01-associated risk for EBV+ Hodgkin lymphoma and infectious mononucleosis [J].
Brennan, Rebekah M. ;
Burrows, Scott R. .
BLOOD, 2008, 112 (06) :2589-2590
[7]  
CARBONE PP, 1971, CANCER RES, V31, P1860
[8]  
CHADBURN A, 1995, AM J PATHOL, V147, P1862
[9]  
CHERQUI D, 1993, TRANSPLANTATION, V56, P1023
[10]  
COX KL, 1995, TRANSPLANTATION, V59, P524